Patent · US Active

HER2 peptide regents and methods

US10858396B2 · kind B2 · utility

0Cited by
0References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 1, 2016
Grant dateDec 8, 2020
Priority date
Expiry dateDec 29, 2036

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/52
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure is directed to HER2-specific peptide reagents, methods for detecting pre-cancer (dysplasia), early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancerous (dysplastic) cells, and/or cancer cells using the peptide reagents.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.